TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35776901

Group type: EXPERIMENTAL
Intervention: Conventional schedule radiation therapy
Number of subjects: 267

Group type: COMPARATOR
Intervention: Hypofractionated radiation therapy
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: EPIC subdomain data
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Baseline cross-sectional data
Number of subjects: 267
Study: 34515448

Group type: EXPERIMENTAL
Intervention: Micro-fragmented autologous adipose tissue injection
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 114
Study: 33241972

Group type: EXPERIMENTAL
Intervention: ECC+ (carrying +15% of body weight in a vest)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ECC
Number of subjects: 32

Group type: COMPARATOR
Intervention: CON
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ECC+
Number of subjects: 32
Study: 33941795

Group type: EXPERIMENTAL
Intervention: NIRS combined with SVM
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: SVM with the top 50 feature wavenumbers
Number of subjects: 82
Study: 32648662

Group type: EXPERIMENTAL
Intervention: Losartan potassium 25 mg for 3 months
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Losartan potassium 25 mg
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 34613330

Group type: EXPERIMENTAL
Intervention: Transanal drainage tube (TDT)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Non-transanal drainage tube (non-TDT)
Number of subjects: 560
Study: 35158293

Group type: EXPERIMENTAL
Intervention: Simultaneous maxillary expansion and mandibular advancement
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 94
Study: 32458310

Group type: EXPERIMENTAL
Intervention: HCAG
Number of subjects: 94

Group type: COMPARATOR
Intervention: CAG
Number of subjects: 94
Study: 34217550

Group type: EXPERIMENTAL
Intervention: HBM-based rational use of drugs training
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 132
Study: 34846525

Group type: EXPERIMENTAL
Intervention: Capecitabine with RT
Number of subjects: 589

Group type: COMPARATOR
Intervention: Capecitabine and oxaliplatin with RT
Number of subjects: 589
Study: 35254628

Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33272334

Group type: EXPERIMENTAL
Intervention: Crushed cartilage graft
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intact cartilage graft (control)
Number of subjects: 46
Study: 35753564

Group type: EXPERIMENTAL
Intervention: Active tDCS (cathodal)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 110
Study: 32586736

Group type: EXPERIMENTAL
Intervention: tezacaftor/ivacaftor
Number of subjects: 97

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 97
Study: 36153030

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) programme comprising 16 twice‐weekly group sessions tailored to the Georgian setting.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study: 34028828

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment and Hall Technique (ART/HT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Dental general anaesthesia (DGA)
Number of subjects: 65
Study: 33278014

Group type: EXPERIMENTAL
Intervention: Kindness to Others
Number of subjects: 97

Group type: COMPARATOR
Intervention: Kindness to Self
Number of subjects: 97

Group type: COMPARATOR
Intervention: Daily Report
Number of subjects: 97
Study: 32016654

Group type: EXPERIMENTAL
Intervention: Acute GA
Number of subjects: 240

Group type: COMPARATOR
Intervention: GA remission
Number of subjects: 240

Group type: COMPARATOR
Intervention: Asymptomatic HUA
Number of subjects: 240

Group type: COMPARATOR
Intervention: Normal control
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Triglyceride and LDL-C
Number of subjects: 240
Study: 33559944

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT) for 6 weeks, 20-25 minutes, 3 times a week (18 sessions)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT)
Number of subjects: 28
Study: 32271290

Group type: EXPERIMENTAL
Intervention: KE group (knees extended)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: KF group (knees flexed)
Number of subjects: 32

Group type: COMPARATOR
Intervention: CON group (control)
Number of subjects: 32
Study: 36173064

Group type: EXPERIMENTAL
Intervention: Repeated-dose intravenous ketamine
Number of subjects: 75
Study: 33759439

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise plus interferential currents (N=25)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Therapeutic exercise only (N=24)
Number of subjects: 49
Study: 36470641

Group type: EXPERIMENTAL
Intervention: M-ROCC (Mindful Recovery OUD Care Continuum)
Number of subjects: 18
Study: 34145939

Group type: EXPERIMENTAL
Intervention: Tight glycaemic control
Number of subjects: 144

Group type: COMPARATOR
Intervention: Conventional glycaemic control
Number of subjects: 144
Study: 35664433

Group type: EXPERIMENTAL
Intervention: Experimental group (sepsis patients)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Observation group (sepsis patients with diabetes mellitus)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 60
Study: 34192942

Group type: EXPERIMENTAL
Intervention: Early surgical fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cast immobilization
Number of subjects: 0
Study: 33004704

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-ketamine (1 μg/kg dexmedetomidine and 0.5 mg/kg ketamine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl-ketamine (2 μg/kg fentanyl and 0.5 mg/kg ketamine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 35737566

Group type: EXPERIMENTAL
Intervention: Visceral fat area (VFA) of ≥100 cm2 in subjects without extensive gastric mucosal atrophy (GA)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Visceral fat area (VFA) in subjects with extensive gastric mucosal atrophy (GA)
Number of subjects: 64
Study: 34233722

Group type: EXPERIMENTAL
Intervention: Cybernic treatment with HAL (40-min walking program performed nine times)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hoist only treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cybernic treatment with HAL
Number of subjects: 30
Study: 35027057

Group type: EXPERIMENTAL
Intervention: Rapid test (GeneXpert GBS system, Cepheid)
Number of subjects: 1628

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1628

Group type: EXPERIMENTAL
Intervention: Rapid test
Number of subjects: 1628
Study: 32469811

Group type: EXPERIMENTAL
Intervention: Aversive movie clip combined with electrical shocks (acute stress stimulation)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Neutral movie clip (control stimulation)
Number of subjects: 35
Study: 36332179

Group type: EXPERIMENTAL
Intervention: Margetuximab (15 mg/kg intravenously once every 3 weeks)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Trastuzumab (6 mg/kg intravenously once every 3 weeks after a loading dose of 8 mg/kg)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Margetuximab in CD16A-158FF patients
Number of subjects: 536

Group type: COMPARATOR
Intervention: Trastuzumab in CD16A-158VV patients
Number of subjects: 536
Study: 34393085

Group type: EXPERIMENTAL
Intervention: DOAC
Number of subjects: 246

Group type: COMPARATOR
Intervention: ASA
Number of subjects: 246
Study: 32932233

Group type: EXPERIMENTAL
Intervention: Power-training group (exercises: countermovement jump and BP throw; sets per exercise: 4-6; repetitions per set: 5-6; load: 40% 1RM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Strength-training group (exercises: SQ and BP; sets per exercise: 4-6; repetitions per set: 2-8; load: 70%-90% 1RM)
Number of subjects: 30
Study: 35627588

Group type: EXPERIMENTAL
Intervention: 0.5% povidone-iodine (PI) preprocedural rinse
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Essential oil (EO) preprocedural rinse
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water as preprocedural rinse
Number of subjects: 10
Study: 34187391

Group type: EXPERIMENTAL
Intervention: Ankle weight intervention (1.1 kg on each ankle) worn during daily activities for 6 months
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard-of-care control group
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ankle weight intervention
Number of subjects: 160
Study: 32624468

Group type: EXPERIMENTAL
Intervention: Self-management app (€ Be‐with‐You')
Number of subjects: 476

Group type: COMPARATOR
Intervention: General health app (€ Sham' app)
Number of subjects: 476
Study: 34784787

Group type: EXPERIMENTAL
Intervention: Oral stimulation and supplemental nursing system
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study: 34003825

Group type: EXPERIMENTAL
Intervention: Knowledge about COVID-19
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Attitude towards COVID-19
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Knowledge of clinical symptoms of COVID-19
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Concern about being infected with COVID-19
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Physical distancing practices
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Knowledge associated with age
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Knowledge associated with urban living
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Attitude associated with information about COVID-19
Number of subjects: 634
Study: 32138607

Group type: EXPERIMENTAL
Intervention: Cluster training (16 sets of 2 repetitions with 1 min rest between sets and 5 min between exercises)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional training (4 sets of 8 repetitions with 5 min rest between sets and exercises)
Number of subjects: 0
Study: 34400254

Group type: EXPERIMENTAL
Intervention: N-of-1 trial treatment regimen
Number of subjects: 0
Study: 616763896

Group type: EXPERIMENTAL
Intervention: Volunteer support for 9 months
Number of subjects: 74

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 74
Study: 35063452

Group type: EXPERIMENTAL
Intervention: CPAP treatment for 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (nasal dilator strips) for 6 months
Number of subjects: 100
Study: 35131817

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 160
Study: 32027349

Group type: EXPERIMENTAL
Intervention: On-time visit adherence (avg days = 28-35 days)
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Late visit adherence (avg days = 36-60 days)
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Very late visit adherence (avg days > 60 days)
Number of subjects: 1178
Study: 34494375

Group type: EXPERIMENTAL
Intervention: 150 min/wk of exercise
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: 225 min/wk of exercise
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: 300 min/wk of exercise
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Behavioral weight maintenance intervention
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 298
Study: 35976398

Group type: EXPERIMENTAL
Intervention: Volumetric early tumor shrinkage (ETS) ≥ 45%
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Diametric early tumor shrinkage (ETS) ≥ 20%
Number of subjects: 253
Study: 34104306

Group type: EXPERIMENTAL
Intervention: Antepartum depression screening using Edinburg Postnatal Depression Scale
Number of subjects: 380
Study: 32227309

Group type: EXPERIMENTAL
Intervention: S. salivarius K12 tablet
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 28
Study: 36428171

Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen deprivation therapy plus abiraterone with or without apalutamide
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (RP without neoadjuvant therapy)
Number of subjects: 124
Study: 33970403

Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 32197766

Group type: EXPERIMENTAL
Intervention: Telehealth follow-up visits
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (office follow-up)
Number of subjects: 66
Study: 616490674

Group type: EXPERIMENTAL
Intervention: GP prescriber
Number of subjects: 928

Group type: COMPARATOR
Intervention: SCC prescriber
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: GPs willing to prescribe
Number of subjects: 928
Study: 35622367

Group type: EXPERIMENTAL
Intervention: Intervention group (10-lb boxes of fruits and vegetables, $10 grocery gift cards, additional $10 gift card for task completion, $25 food preparation tool)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intervention group compared to control group
Number of subjects: 68
Study: 35998937

Group type: EXPERIMENTAL
Intervention: PENG block with 20 mL of 0.5% ropivacaine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham injection with 5 mL of 0.9% normal saline
Number of subjects: 68
Study: 36373628

Group type: EXPERIMENTAL
Intervention: Smartphone application providing a structured resilience curriculum for 3 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waitlist-control group
Number of subjects: 20
Study: 33676417

Group type: EXPERIMENTAL
Intervention: Shoulder pain on arm activity (VAS)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Constant-Murley score (CS)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Simple Shoulder Test (SST)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Shoulder pain at rest (VAS)
Number of subjects: 193
Study: 33355261

Group type: EXPERIMENTAL
Intervention: QPM seed with consumption targeting intervention
Number of subjects: 610

Group type: COMPARATOR
Intervention: QPM seed only
Number of subjects: 610
Study: 36174006

Group type: EXPERIMENTAL
Intervention: Tritipyrum line (Ka/b)(Cr/b)‐5
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Triticale lines (M45, 4115, 4108)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Tritipyrum lines
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: M45 triticale and tritipyrum (Ka/b)(Cr/b)‐5
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Spike number
Number of subjects: 17
Study: 33618721

Group type: EXPERIMENTAL
Intervention: Rehabilitation education through social media (WhatsApp channel and group) for 1 month
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group received discharge education via pamphlets and face-to-face training
Number of subjects: 60
Study: 36214032

Group type: EXPERIMENTAL
Intervention: Group A (120 kVp, 370 mgI/ml CM)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Group B (100 kVp, 350 mgI/ml CM)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Group C (80 kVp, 320 mgI/ml CM)
Number of subjects: 150
Study: 34036845

Group type: COMPARATOR
Intervention: GnRH agonists (Triptorelin or Leuprorelin 3.75 mg every 4 weeks for 6 months)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Dienogest (2 mg/day for at least 6 months)
Number of subjects: 146
Study: 32059943

Group type: EXPERIMENTAL
Intervention: Revision cubital tunnel surgery
Number of subjects: 17

Group type: COMPARATOR
Intervention: Primary cubital tunnel surgery (control cohort)
Number of subjects: 17
Study: 34296334

Group type: EXPERIMENTAL
Intervention: CSNAT-I (Carer Support Needs Assessment Tool Intervention)
Number of subjects: 130
Study: 33567657

Group type: EXPERIMENTAL
Intervention: Frequent communication with devices
Number of subjects: 725

Group type: COMPARATOR
Intervention: Infrequent communication with devices
Number of subjects: 725

Group type: COMPARATOR
Intervention: No communication devices
Number of subjects: 725
Study: 32519832

Group type: EXPERIMENTAL
Intervention: Plyometric training (PLY) once a week for 12 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study: 34854308

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4330

Group type: EXPERIMENTAL
Intervention: Baseline GDF-15 levels
Number of subjects: 4330
Study: 36058695

Group type: EXPERIMENTAL
Intervention: Common burn diet enteral immunonutrition group (n=225)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Severe burn diet enteral immunonutrition group (n=23)
Number of subjects: 500
Study: 32725293

Group type: EXPERIMENTAL
Intervention: 2 portions of fish per week (140 g per portion)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 1 portion of fish per week (140 g per portion)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No fish
Number of subjects: 49
Study: 35710254

Group type: EXPERIMENTAL
Intervention: Kiplin digital intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual supervised physical activity programme
Number of subjects: 50
Study: 33293297

Group type: EXPERIMENTAL
Intervention: Average accelerations (accelerometer-based physical activity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (fraction of accelerations >425 milligravities)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sedentary behavior (metabolic equivalent task ≤1.5)
Number of subjects: 0
Study: 36445316

Group type: EXPERIMENTAL
Intervention: Nurse-led motor function rehabilitation program (7 consecutive days, twice daily for 30 minutes)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 104
Study: 34110395

Group type: EXPERIMENTAL
Intervention: Oncologist-directed interventions to facilitate discussion of emotions
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Patient-directed interventions to facilitate discussion of emotions
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: General oncologist treatment style
Number of subjects: 141
Study: 34523017

Group type: EXPERIMENTAL
Intervention: Carbon ion reirradiation (CIRT) - 45 Gy (RBE; 15 fractions)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Photon reirradiation (FSRT) - 39 Gy (13 fractions)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Comparison of CIRT vs FSRT
Number of subjects: 78

Group type: COMPARATOR
Intervention: Adverse events for FSRT
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Adverse events for CIRT
Number of subjects: 78
Study: 32585668

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure (SBP) reduction (goal 110-139 mm Hg) using intravenous nicardipine
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard systolic blood pressure (SBP) reduction (goal 140-179 mm Hg)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure (SBP) reduction
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard systolic blood pressure (SBP) reduction
Number of subjects: 1000
Study: 36445398

Group type: EXPERIMENTAL
Intervention: Pregnenolone 300 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Pregnenolone 500 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Pregnenolone (both doses)
Number of subjects: 43
Study: 33612489

Group type: EXPERIMENTAL
Intervention: Child-to-child approach
Number of subjects: 397

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 397
Study: 32830462

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 supplementation (20,400 IU every other day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low-dose vitamin D3 supplementation (400 IU every other day)
Number of subjects: 38
Study: 35611581

Group type: EXPERIMENTAL
Intervention: Pre-surgical aerobic dance-based exercise programme (PSADBE) and physical activity counselling (PAC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Physical activity counselling (PAC)
Number of subjects: 34
Study: 33787191

Group type: EXPERIMENTAL
Intervention: Soft and prolonged massage with Roghan‐i‐Bābūna
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dry cupping on alternate days for 15 minutes
Number of subjects: 48

Group type: COMPARATOR
Intervention: Both interventions (Soft and prolonged massage and Dry cupping)
Number of subjects: 48
Study: 33296549

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA) (2.5‐5 mg/kg/d)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) (7.5‐15 mg/week)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Acitretin (ACT) (25‐50 mg/d)
Number of subjects: 75
Study: 32868146

Group type: EXPERIMENTAL
Intervention: Breathy phonation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Neutral phonation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Flow phonation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pressed phonation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Typical loudness condition
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Loud loudness condition
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Soft loudness condition
Number of subjects: 13
Study: 34552657

Group type: EXPERIMENTAL
Intervention: Viola flower syrup (VFS) for four weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG) for four weeks
Number of subjects: 140
Study: 36037779

Group type: EXPERIMENTAL
Intervention: Inhibitory application of kinesio tape plus static stretching
Number of subjects: 15

Group type: COMPARATOR
Intervention: Static stretching
Number of subjects: 15
Study: 34087150

Group type: EXPERIMENTAL
Intervention: Copanlisib plus rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus rituximab
Number of subjects: 0
Study: 32402684

Group type: EXPERIMENTAL
Intervention: Oral ferrous fumarate (FF) 200 mg three times a day (total daily dose: 195 mg elemental iron)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral ferrous gluconate (FG) 695 mg twice a day (total daily dose: 160 mg elemental iron)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM) 1000 mg elemental iron (single dose)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral ferrous fumarate (FF)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral ferrous gluconate (FG)
Number of subjects: 120